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Abstract

*Correspondence to:

Immune-mediated activation of tryptophan (TRYP) catabolism via the kynurenine pathway (KP) is a consistent finding in all inflammatory disorders. Several studies by our group and others have examined the
neurotoxic potential of neuroreactive TRYP metabolites, including quinolinic acid (QUIN) in neuroinflammatory neurological disorders, including Alzheimer’s disease (AD), multiple sclerosis, amylotropic lateral
sclerosis (ALS), and AIDS related dementia complex (ADC). Our current work aims to determine whether
there is any benefit to the affected individuals in enhancing the catabolism of TRYP via the KP during an
immune response. Under physiological conditions, QUIN is metabolized to the essential pyridine nucleotide, nicotinamide adenine dinucleotide (NAD+), which represents an important metabolic cofactor and
electron transporter. NAD+ also serves as a substrate for the DNA ‘nick sensor’ and putative nuclear repair
enzyme, poly(ADP-ribose) polymerase (PARP). Free radical initiated DNA damage, PARP activation and
NAD+ depletion may contribute to brain dysfunction and cell death in neuroinflammatory disease.
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The Kynurenine Pathway in
Neuroinflammatory Disorders

TRYP is the least abundant amino acid in mammalian organisms, and accounts for only 1–1.5% of the total protein
amino acid content. However, it was not until the late 1970s
and 1980s that KP generated considerable interest among
neuroscientists, since it was discovered that QUIN and kynurenine acid (KYNA), (two metabolites of the KP) exhibited significant and opposing actions on neuronal cells. QUIN
is a selective agonist at the N-methyl D-aspartate (NMDA)
site of the excitatory NMDA (glutamate subtype) receptor,
while KYNA is an antagonist at both the NMDA and glycine
site of this ionotropic receptor (Guillemin, 2012). Activation
of the NMDA receptor has been shown to permeate cells
to Ca2+, Na+ and K+ ions. Increased intracellular Ca2+ influx
has been shown to activate several secondary messenger signalling pathways leading to synaptic alterations. Moreover,
increased intracellular Ca2+ influx due to excessive NMDA
receptor activation can induce excitotoxicity and neuronal
cell death in several neurodegenerative diseases (Braidy et
al., 2010).
In humans, CNS QUIN levels are increased in several neurological disorders including AD, depression, epilepsy, autism, schizophrenia, and patients are more susceptible to suicide risk (Brundin et al., 2016). This has led to the hypothesis

that the increase in CNS levels of QUIN is pivotal to the
pathogenesis of these disorders through its mode of action at
the NMDA receptor. QUIN may also induce toxicity to brain
cells via exogenous free radical production. On the contrary,
reduced levels of KYNA have been reported in neurological
disorders such as Huntington’s disease (HD), and AD. It has
been suggested that the development of inflammatory mediated neuropathology is correlated to changes in the ratio of
KYNA to QUIN rather than QUIN levels alone.
Given the extent that the KP influences neuronal function,
identifying the site of TRYP metabolite production during
CNS inflammation is beneficial to gain a sound understanding of inflammatory mediated neuropathology. These metabolites may have originated either from upregulated TRYP catabolism within the CNS during inflammation, or may cross
the blood-brain barrier after being systemically produced. It
has been reported that CNS levels of KP metabolites increase
independently of their systemic concentration during neuroinflammation, thus suggesting that KP metabolites can be
present at upregulated levels locally within the CNS.

De novo NAD+ Synthesis via the Kynurenine
Pathway

QUIN is converted to nicotinic acid mononucleotide
(NaMN) by the enzyme quinolinic acid phosphoribosyl
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transferase (QPRT) in the presence of Mg2+. Further transformation leading to the synthesis of the parent molecule
of the pyridine nucleotide, NAD+, appears to be nuclear,
mitochondrial, and golgi specific, by nicotinamide mononucleotide adenyl transferase (NMNAT1, 2, and 3) in the
presence of ATP to produce desamido-NAD+. In the presence of glutamine desamido-NAD is amidated to the parent pyridine nucleotide, NAD+, as the final product of the
KP In addition to its de novo synthesis for TRYP, NAD+
can also be synthesised from either one of three routes:
(1) nicotinic acid (NA), which is then converted to NAD+
via the three-step Preiss-Handler pathway; (2) the enzyme
nicotinamide phosphoribosyl transferase (NAMPT) converts NM to nicotinamide mononucleotide (NMN) and
then to NAD+ by the action of NMNAT1, 2, and 3 in the
presence of ATP, or (3) phosphorylation of nicotinamide
riboside (NR) to NMN by NR kinases (NRKs) (Ratajczak
et al., 2016) (Figure 1A and B). In spite of the potential
for NAD+ production from vitamins, the de novo synthesis
of NAD+ from TRYP appears to be more important than
NAD+ production from vitamins under normal physiological conditions.

Source of Tryptophan Catabolism During
Neuroinflammation

The KP is not fully expressed in all brain cells. To date, the
only cells in the CNS demonstrated to possess the enzyme
3-hydroxyanthranilic acid oxygenase (3-HAO) which generates QUIN are astroglial and microglia/macrophages/
dendritic cells (Braidy et al., 2016). Therefore, the increase
in TRYP catabolism observed during neuroinflammation
must necessarily involve these two cell types.
IFN-γ is the primary activating factor of macrophage/microglial/dendritic cells in the CNS and elsewhere, increasing their antimicrobial activity through the modulation and
upregulation of a variety of activities including, enhanced
production of reactive oxygen species (ROS), increased nitric oxide synthase activity, upregulation of MHC antigens,
secretion of cytokines such as interleukin (IL)-1β, IL-6,
tumour necrosis factor-α (TNF-α), platelet activating factor (PAF), macrophage chemotactic protein (MCP-1), and
secretion of other biologically active proteins such as complement pathway components. Indoleamine 2,3 dioxygenase (IDO) is the primary enzyme of the KP, and is potently
induced by IFN-γ in both astrocytes and inflammatory cells
leading to a marked increase in KP metabolites in these
cells. IFN-γ activated microglial/macrophages/dendritic
cells will readily catabolize TRYP through induction of
IDO, producing significant amounts of metabolic neuroreactive intermediates such as KYN, anthranilic acid (AA),
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3-hydroxykynurenine (3-HK), 3-hydroxyanthranilic acid
(3-HAA), and QUIN. The KP also leads to the production
of the metal chelating agent, picolinic acid (PIC) (Schwarcz
and Stone, 2016).
Astrocytes also readily degrade TRYP in response to
IFN-γ treatment through the induction of IDO. KYN appears to be the main metabolite found in the supernatants
of IFN-γ treated astroglial cells. However, significant but
trace amounts of AA from an astrocytoma cell line, and
QUIN, from human foetal brain cultures have also been reported (Guillemin et al., 2000).
It has been suggested that TRYP catabolism increased in
some cells to decrease TRYP concentrations in the microenvironment thereby reducing the availability of this essential
amino acid for microbial metabolism. However, this hypothesis has been challenged by others. One of the products
of TRYP catabolism, 3-HAA, can function as an effective
antioxidant, and potential nitric oxide synthase inhibitor.
Production of this metabolite may therefore serve to reduce
non-specific oxidative damage at the site of neuroinflammation induced by activated mononuclear phagocytes, and may
explain the increased TRYP catabolism under these conditions (Krause et al., 2011). However, increased secretion of
KYN and QUIN under these circumstances has not been
confirmed. Moreover, IFN-γ induced IDO TRYP catabolism
has been shown to increase cellular NAD+ concentrations in
an astroglioma cell line (Grant et al., 1999).
Despite the consolidated role of the classic KP metabolites (e.g., KYN, KYNA, 3-HAA, and QUIN) during immune responses, it has recently emerged that cinnabarinic
acid (CA) is crucial for immune system functions (Hiramatsu et al., 2008; Fazio et al., 2014). It has been shown that
CA can be produced by stimulated human PBMCs. CA can
also be produced via non-enzymatic reactions under oxidative conditions. In inflammatory cells such as neutrophils,
co-expression of IDO and other enzymes involved in the
formation of free radicals may divert the KP away from the
production of QUIN, and instead towards CA over PIC or
QUIN (Lowe et al., 2014). Therefore, concomitant implementation of NAD+ levels could be enhanced by increased
CA amounts.
Poly(ADP-ribose) polymerase and NAD+ depletion: Double strand DNA breaks caused by excessive oxidative damage activate the PARP enzyme. Neuronal cells exposed to
pathological concentrations of the excitotoxic neurotransmitter, glutamate show both an increase in intracellular
oxidative stress and PARP activity. PARP is a protein modifying nucleotide polymerising enzyme found abundant in
the nucleus, with approximately one molecule of enzyme
per 1,000 base pairs. PARP, along with DNA dependent
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Figure 1 The nicotinamide adenine dinucleotide (NAD+) metabolome.
(A) The de novo synthesis of NAD+ from TRYP appears to be more important than NAD+ production leading to the production of several neuroreactive
compounds such as the neurotoxin and NMDA receptor agonist, quinolinic acid, and the NMDA receptor antagonist, kynurenine acid. (B) NAD+ can also
be produced by the salvage of nicotinic acid, nicotinamide and nicotinamide riboside. (C) PARP activity following DNA damage utilized NAD+ as the essential
substrate to repair damaged DNA. Hyperactivation of PARP due to accumulation of free radicals can lead to cell death by NAD+ depletion, and energy restriction. NMDA: N-methyl D-aspartate; PARP: poly(ADP-ribose) polymerase; ROS: reactive oxygen species; TRYP: tryptophan.

protein kinases appears to play an important role in maintaining genomic integrity (Massudi et al., 2012). However,
the precise physiological roles of PARP are not completely
understood.
As a ‘DNA nick sensor’, PARP rapidly binds to DNA
strand breaks and is activated. Activated PARP uses
up NAD + (and NADP + ), exclusively as substrate to
poly(ADP-ribosylate) itself and a number of nuclear proteins that are involved in the repair of DNA, releasing nicotinamide as a by-product. Recent evidence suggests that
polyADP-ribosylation of histones or transcription factors
may also be involved in nuclear receptor signalling (Morales
et al., 2014) (Figure 1C).
A significant decrease in intracellular NAD+ levels has

been reported in the brain and a variety of cell types as a
result of DNA strand breaks and PARP activation following
exposure to free radical generators, excitotoxins, infections, AD, and during inflammation or ageing (Abeti and
Duchen, 2012; Braidy et al., 2014). Increased PARP activity
resulting in decreased NAD+ has been shown to decrease
ATP and neurotransmitter levels in the brain, as well as
cell lysis and death. Inhibition of PARP activity following
oxidant injury has been shown to preserve NAD+ and ATP
levels, prevent cell lysis, although damage to the DNA was
not prevented. Additionally, at low levels of oxidant, PARP–/–
cells survived better than PARP+/+ cells, suggesting that loss
of NAD+ may be a cause of cell death. Elevated levels of free
radicals, pro oxidants, and excitotoxins have been reported
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in inflammatory brain disorders, and in most cases, DNA
damage has been observed. This suggests that NAD+ depletion through PARP activation may play a crucial role
in CNS dysfunction and pathology under these conditions
(Massudi et al., 2012).

Conclusion

Immune activation of macrophage/microglial/dendritic
cells results in a marked increase in their generation of
ROS. Elevated extracellular fluid levels of these free radicals have been implicated in the cause of tissue damage
during inflammation in several disorders. Damage to
surrounding tissue, including astrocytes and neurons in
the CNS, may occur in response to inflammation in the
CNS. As well, the non-discriminating nature of these free
radicals may induce damage to the activated macrophage
itself. At least one study has reported an increase in PARP
activity in IFN-γ activated macrophages, suggesting that
DNA damage has occurred with a corresponding increase
in the rate of NAD+ catabolism.
The cellular immune response potentially increases NAD+
catabolism in cells at the site of inflammation. A mechanism
by which this important nucleotide could be regenerated appears to be essential to the continued viability of cells within
this environment. Therefore therapeutic strategies targeted at
inhibiting KP metabolism alone may not be sufficient for the
resolution of symptomatic disease. However, inhibition of
QUIN production may need to be coupled to the administration of a suitable NAD+ precursor. This combination may
then effectively reduce QUIN production, while maintaining
optimal NAD+ levels.
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